Section Edited by Claudia Palena, PhD and Eric Tartour, MD, PhD
Basic and translational cancer immunology articles cover new tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response characterization and quantification, cancer and inflammation, preclinical models, pre-clinical evaluations of individual cancer therapeutics and combinations (chemotherapy, radiotherapy, immune checkpoint inhibitors and stimulators, and other antigen-specific immunotherapies). These should generally be focused on new findings in the context of the immune system and on correlations with measures of tumor reduction or growth. Studies leading to mechanistic understanding or novel development of agents and combination therapies are encouraged. Studies with in vivo experiments in more than one animal tumor model are preferred.
Inhibition of Cbl-b restores effector functions of human intratumoral NK cellsSofia Tundo, Marcel Trefny, Andrijana Rodić, Olivia Grueninger, Nicole Brodmann, Anastasiya Börsch, Clara Serger, Jonas Fürst, Melanie Buchi, Katarzyna Buczak, Alex T Müller, Lisa Sach-Peltason, Leyla Don, Petra Herzig, Didier LardinoisSee the full list of authors
17 November 2024
Morphine treatment restricts response to immunotherapy in oral squamous cell carcinomaLisa A McIlvried, Andre A Martel Matos, Mona M Yuan, Megan A Atherton, Fendi Obuekwe, Marci L Nilsen, Amin Reza Nikpoor, Sebastien Talbot, Tullia C Bruno, David N Taggart, Lorin K Johnson, Robert L Ferris, Dan P Zandberg, Nicole N Scheff
17 November 2024
FOXA1 enhances antitumor immunity via repressing interferon-induced PD-L1 expression in nasopharyngeal carcinomaJunshang Ge, Ying Liu, Pan Chen, Zhaoyang Zeng, Guiyuan Li, Wei Xiong, Mei Yi, Bo Xiang
14 November 2024
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expressionMalte Roerden, Andrea B Castro, Yufei Cui, Noora Harake, Byungji Kim, Jonathan Dye, Laura Maiorino, Forest M White, Darrell J Irvine, Kevin Litchfield, Stefani Spranger
9 November 2024
Bendamustine–rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS–STING activation in diffuse large B-cell lymphomaRuipei Xiao, Wenli Zhao, Wei Lin, Yudian Xiao, Jie Ren, Yang Zhou, Wei Meng, Enguang Bi, Ling Jiang
9 November 2024
Depletion of conventional CD4 T cells is required for robust priming and dissemination of tumor antigen-specific CD8 T cells in the setting of anti-CD4 therapyDelaney E Ramirez, Christo P C Dragnev, Tyler G Searles, Nathaniel Spicer, Tiffany Chen, J Louise Lines, Aaron R Hawkes, Wilson L Davis, Asmaa Mohamed, Keisuke Shirai, Joseph D Phillips, Pamela C Rosato, Yina H Huang, Mary Jo Turk
9 November 2024
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinomaRicardo DeAzevedo, Madeline Steiner, Broderick X Turner, Arthur Liu, Sherwin Newton, Joanna Schmidt, Rachel Fleming, Angelica Tolentino, Ahmed O Kaseb, Michael A Curran
30 October 2024
Inhibitory Fcγ receptor deletion enhances CD8 T cell stemness increasing anti-PD-1 therapy responsiveness against glioblastomaKeun Bon Ku, Chae Won Kim, Yumin Kim, Byeong Hoon Kang, Jeongwoo La, In Kang, Won Hyung Park, Stephen Ahn, Sung Ki Lee, Heung Kyu Lee
26 October 2024
Targeting CD93 on monocytes revitalizes antitumor immunity by enhancing the function and infiltration of CD8 T cellsDa Jiang, Aiqi Huang, Bai-Xi Zhu, Jiangling Gong, Yong-Hao Ruan, Xing-Chen Liu, Limin Zheng, Yan Wu
23 October 2024
Cancer-associated foam cells hamper protective T cell immunity and favor tumor progression in human colon carcinogenesisElena Daveri, Barbara Vergani, Luca Lalli, Giulio Ferrero, Elena Casiraghi, Agata Cova, Marta Zorza, Veronica Huber, Manuela Gariboldi, Patrizia Pasanisi, Simonetta Guarrera, Daniele Morelli, Flavio Arienti, Marco Vitellaro, Paola A CorsettoSee the full list of authors
12 October 2024